Radiation Therapy and Bortezomib and Cetuximab With or Without Cisplatin to Treat Head and Neck Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01445405|
Recruitment Status : Completed
First Posted : October 3, 2011
Last Update Posted : September 6, 2019
Bortezomib acts on molecules in head and neck cancer cells that are important for the cells growth and survival. The drug may help make the cancer more sensitive to radiation and other chemotherapy drugs.
Cetuximab is a monoclonal antibody that has increased the effectiveness of radiation treatment in patients with head and neck cancer in clinical trials.
Cisplatin has shrunk head and neck cancers and improved treatment response and survival when combined with radiation treatment.
To determine the highest safe dose of bortezomib when combined with cetuximab without or with cisplatin and with radiation in patients with advanced head and neck cancer.
To examine the benefits and side effects of these drug combinations with radiation in patients with advanced head and neck cancer.
Patients 18 years of age and older with advanced Stage IV head and neck cancer who have not previously had neck radiation.
Patients will be assigned sequentially to one of two treatment groups: Group A receives bortezomib and cetuximab beginning the week before, and for the duration of, radiation therapy; Group B receives bortezomib, cetuximab and cisplatin beginning the week before, and for the duration of, radiation therapy.
- Cetuximab is given as a 2-hour infusion through a vein (intravenously, IV) for the first dose and then over 1 hour for subsequent weekly doses.
- Bortezomib is given as an injection into a vein over about 5 seconds, twice a week for 2 weeks, followed by a 1-week rest for a total of three 3-week treatment cycles during radiation.
- Cisplatin is given in once a week as a 1-hour IV infusion
- Radiation therapy is given 5 days a week for 7 to 8 weeks.
- Until 2 weeks after treatment ends, patients are followed once a week including a physical examination, review of treatment side effects, and blood tests.
- For 2 months after treatment ends, patients may need to return to the hospital for medical evaluation and supportive care, depending on their condition.
- 8-weeks after treatment ends, patients return for evaluation with a history and physical examination; blood tests; ear, nose and throat evaluation and endoscopy; CT or MRI scan, or both, of the neck and chest; and, if indicated, a PET scan....
|Condition or disease||Intervention/treatment||Phase|
|Carcinoma, Squamous Head and Neck Cancer Oral Cancer Laryngeal Cancer Pharyngeal Cancer||Drug: Bortezomib (Velcade, PS-341) Drug: Cetuximab Drug: Cisplatin Procedure: Radiation Therapy||Phase 1|
Show Detailed Description
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||3 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Phase I Study of Bortezomib and Cetuximab Without or With Cisplatin in Combination With Radiation Therapy for Advanced Head and Neck Cancer|
|Study Start Date :||February 5, 2008|
|Actual Primary Completion Date :||August 27, 2010|
|Actual Study Completion Date :||August 27, 2010|
- Evaluate feasibility/toxicities of combining proteasome inhibitor bortezomib with cetuximab without/with cisplatin concurrent with radiation for therapy of Pts with advanced SCCHN, and identify MTD for bortezomib for further clinical phase 2 dev...
- 1) Evaluate objective response rate, progression-free survival/overall survival with the above regimen. 2) Determine effects of bortezomib with cetuximab or with cetuximab/ cisplatin to inhibit activation of NF-kB, EGFR, MAPK, and STAT3 signal p...
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01445405
|United States, Maryland|
|National Institutes of Health Clinical Center, 9000 Rockville Pike|
|Bethesda, Maryland, United States, 20892|
|Principal Investigator:||Carter Van Waes, M.D.||National Institute on Deafness and Other Communication Disorders (NIDCD)|